Antibody-drug conjugates (ADCs) represent one of the most promising advancements in targeted cancer therapy. By combining the specificity of monoclonal antibodies with the potent cell-killing ability of cytotoxic drugs, ADCs can deliver treatment directly to cancer cells, minimizing damage to…
